1Diekema DJ,Messer SA, Hollis RJ,et al. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voricon azole, and amphotericin B against 448 recent clinical isolates of filamentous fungi[J]. J Clin Microbiol, 2003, 41, 3623- 3626.
2Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens [J]. J Clin Microbiol, 1998,36:198-202.
3Pfaller MA, Messer SA, Hollis RJ,et al. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp and othert filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000 [J]. Antimierob Agents Chemother, 2002, 46:1032-1037.
4Abi Said D, Anaissie E, Unzun O, et al. The epidemiology of hematogenous candidiasis caused by different Cadida species [J]. Clin Infect, 1997,24 : 1122-1128.
5Hajjeh RA,Brandt ME,Pinner RW. Emergence of crypococcal disease: epidemiologic perspectives 100 years after its discovery[J]. Epidemiology, 1995,17:303-320.
6Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretive breakpoints for antifungal susceptibility testing: con ceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections[J]. Clin Infect, 1997,24: 235-247.
7National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts[S]. Approved document M27-A2. 2nd ed. NCCLS, 2002.
8National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi[S]. Approved document M38-A. NCCLS,2002.
9Shawn AM, Ronald NJ, Thomas RF. International Surveillance of Candida spp and Aspergillus spp: report from the SENTRY Antimicrobial Surveillance Program ( 2003 ) [ J ]. J Clin Microbiol, 2006,1782-1787.
10H P R, L Y-J, C Y-C, et al. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan Program data from 2003[J]. Antimicrob Agents Chemother,2005,512-517.
